Trial Profile
A first-in-man phase I study of RORgamma agonists for the treatment of cancer
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 06 May 2015
Price :
$35
*
At a glance
- Drugs Retinoic acid receptor gamma agonists (Primary)
- Indications Cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- 30 Apr 2015 According to a Lycera media release, this trial is expected to begin in mid-2016.
- 30 Apr 2015 Planned initiation date changed from 1 Dec 2015 to 1 Jun 2016 according to a Lycera Corporation media release.
- 17 Feb 2015 New trial record